Wesana Health Holdings Inc. (CNSX:WESA) announced that following the successful completion of an initial tranche of its previously announced private placement, the company has determined to move forward with a strategic review of Wesana’s care delivery division. Strategic Rationale for Clinics and Other Care Delivery Asset Review: Feedback from the U.S. Food and Drug Administration (“FDA”) validates the company's strategic plan for simplification and growth. Given the clarity provided by FDA in the pre-IND meeting, and the Company’s increased focus on drug development, Wesana has commenced a strategic review of the Company’s assets with a focus on reviewing Wesana’s care delivery division. The Company is reviewing strategic alternatives including, but not limited to, a sale of all the assets under the care delivery division, including: Wesana Clinics – a network of psychiatrist-led mental health clinics focused on serving the community through the delivery of personalized innovative psychiatric care, inclusive of ketamine therapy, medication management, psychotherapy, cognitive testing, and pharmacogenetic testing. Wesana Solutions – a medical-grade clinical SaaS platform focused on improving mental healthcare through facilitating access to leading edge clinical protocols and tracking their efficacy. In concert with EMRs and practice management systems, Wesana Solutions is intended to be used in clinics delivering psychedelics and related therapies, targeting the developing international psychiatric clinic and research market. PsyTech Connect – a leading community for the clinical use of psychedelics with over 8,000 actively engaged professionals Zed Wang, Chief Financial Officer said, “We believe now is the correct time to review all strategic options to maximize shareholder value and financial resources. A clear focus will allow Wesana to optimize resources as we look to expand the lead indication associated with SANA-013 and allow the clinics to realize their growth potential”.